Alessandro Padovani, MD, PhD, discusses the utility and value of biomarker assessments in distinguishing AD, particularly mild cognitive impairment due to AD from other neurodegenerative diseases. He describes the MRI and PET biomarker profiles typically associated with AD, as well as appropriate and inappropriate uses of amyloid PET imaging. Professor Padovani then outlines the role of CSF analysis in the diagnoses of AD, and the predictive value of these biomarkers, before discussing the potential future role of plasma biomarkers as screening tools.
The panel discuss using imaging and fluid biomarkers in their clinical practice and the common challenges with the availability and acceptability of these assessments.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.